Translational studies on circulating immune cells from TCHL study patients identified that PD-1-inhibited ADCC-capable immune cells were associated with lower baseline TIL levels as a potential biomarker of response to therapy, providing evidence that immune suppression has a role to play in pCR to neo-adjuvant therapy in HER2+ breast cancer [33]. The gene discussed is ERBB2; the disease is breast cancer.